-+ 0.00%
-+ 0.00%
-+ 0.00%

Crystalys Therapeutics raises $130 million Series B led by Frazier, joined by HBM Healthcare Investments

PUBT·07/23/2026 07:52:43
Listen to the news
Crystalys Therapeutics raises $130 million Series B led by Frazier, joined by HBM Healthcare Investments
  • Crystalys Therapeutics closed an oversubscribed USD 130 million Series B financing with participation from HBM Healthcare Investments, part of HBM Partners AG.
  • San Diego-based Crystalys is a clinical-stage biopharmaceutical company developing dotinurad, a once-daily oral URAT1 inhibitor for gout.
  • Proceeds earmarked for global Phase 3 development and commercialization preparation for dotinurad, including the RUBY and TOPAZ trials.
  • Round led by Frazier Life Sciences with additional participation from Wellington Management and other healthcare-focused investors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Partners AG published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.